Sign in
CompletedNo phase

MitraClip China PMS

Key facts

Who runs it
Abbott Medical Devices
Where
China5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
51 people enrolled
Started
6 Dec 2021
Ended
7 Mar 2025
Type of study
Interventional
Treatments tested
  • MitraClip procedure
Record updated
15 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Subjects is eligible to receive the MitraClip per the current approved MitraClip System IFU. (If any update or amendment on the IFU, the latest version of IFU shall be followed.)
  • Subject is 18 years-old or above
  • Subjects who give consent for study procedure

Who cannot take part

  • Subject is unlikely to survive the protocol follow up period of 12-months after device implant
  • Subject with rheumatic mitral valve disease
  • Subject cannot tolerate procedural anticoagulation or anti-platelet regimen
  • Subject with active endocarditis of mitral valve
  • Subject with echocardiographic evidence of intracardiac, IVC or femoral venous thrombus
  • Subject has insufficient or lost ability to maintain their will and rights
  • Subject is illiterate
  • Pregnant or nursing subjects and those who plan pregnancy during the study follow-up period
  • Subject participates in another clinical study that may impact the follow-up or results of this study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The MitraClip System is the first commercially available catheter-based option for the treatment of MR. The MitraClip System was developed as an alternate percutaneous technology which may serve as a viable therapeutic option for open-heart surgery. Treatment with the MitraClip device allows patients to undergo a less invasive procedure that can mechanistically reduce MR and allow for improved quality of life. The MitraClip procedure is performed under general anesthesia without the use of a heart-lung machine, with recovery typically lasting two to three days.

The group in the trial

  • MitraClipTreatment being tested

    Subject will receive MitraClip procedure with MitraClip NTR System or MitraClip XTR System.

    Treatment: MitraClip procedure

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-Center, Single-Arm, Post Market Study of the MitraClip System for the Treatment of Symptomatic Mitral Regurgitation in China
Record updated
15 December 2025